Document is current
Any future updates will be listed below
-
Authors
Kandane-Rathnayake, Rangi https://orcid.org/0000-0001-5397-1482
Milea, Dominique
Louthrenoo, Worawit
Hoi, Alberta https://orcid.org/0000-0002-9416-7383
Golder, Vera
Cho, Jiacai https://orcid.org/0000-0002-4477-3430
Lateef, Aisha
Luo, Shue-Fen
Wu, Yeong-Jian Jan
Hamijoyo, Laniyati https://orcid.org/0000-0002-1310-674X
Sockalingam, Sargunan
Li, Zhanguo
Navarra, Sandra https://orcid.org/0000-0003-0094-8654
Zamora, Leonid
Harigai, Masayoshi
Katsumata, Yasuhiro https://orcid.org/0000-0003-1654-0119
Chan, Madelynn
Hao, Yanjie https://orcid.org/0000-0001-8715-259X
Zhang, Zhuoli https://orcid.org/0000-0001-7219-9141
O’Neill, Sean
Goldblatt, Fiona
Oon, Shereen
Xu, Xiaomeng
Navarro Rojas, Aldo A
Bae, Sang-Cheol https://orcid.org/0000-0003-4658-1093
Lau, Chak Sing https://orcid.org/0000-0001-6698-8355
Nikpour, Mandana
Morand, Eric https://orcid.org/0000-0002-9507-3338
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03138941 at ClinicalTrials.govDocuments that mention this clinical trial
Clinical characteristics and treatment response of patients with SLE complicated with thrombotic thrombocytopenic purpura
https://doi.org/10.1136/lupus-2025-001740
Impact of glucocorticoid dose threshold in definition of lupus low disease activity state: a multinational observational cohort study
https://doi.org/10.1136/lupus-2025-001714
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2024-001363
-
Funding
Funding for this research was provided by:
UCB Pharma
AstraZeneca
EMD Serono
GSK (217856)
Eli Lilly
Bristol Myers Squibb
Janssen
- License Information
